An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency

Theranostics

Volumn 9, Issue 1, 2019, Pages 210-231

  Shen, Chenguang ^a,b   Zhang, Minwei ^a,c   Chen, Yuanzhi ^a   Zhang, Limin ^a   Wang, Guosong ^a   Chen, Junyu ^a   Chen, Siyuan ^a   Li, Zizhen ^a   Wei, Feixue ^a   Chen, Jing ^c   Yang, Kunyu ^d   Guo, Shuxin ^a   Wang, Yujing ^a   Zheng, Qingbing ^a   Yu, Hai ^a   Luo, Wenxin ^a   Zhang, Jun ^a   Chen, Honglin ^a,e   Chen, Yixin ^a   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^d Xiamen International Travel Health Care Centre   (China)

^e THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Broadly neutralizing antibodies; Hemagglutinin; IgM; Influenza B virus; Receptor binding site

Indexed keywords

C7G6 IMMUNOGLOBULIN M BROADLY NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; OSELTAMIVIR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOGLOBULIN CLASS SWITCHING; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA B; INFLUENZA B VIRUS; MOUSE; MUSTELA PUTORIUS FURO; NONHUMAN; RECEPTOR BINDING SITE; SURVIVAL RATE; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH, DEVELOPMENT AND AGING; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORTHOMYXOVIRUS INFECTION; PASSIVE IMMUNIZATION; PROCEDURES; SERODIAGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA B VIRUS; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME;

EID: 85059504131     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.28434     Document Type: Article

References (57)

1. Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses. 2015;9 Suppl 1:3-12.
2. Pan Y, Zhang Y, Yang P, Qian H, Shi W, Wu S, et al. Epidemiological and Phylogenetic Characteristics of Influenza B Infection in Severe Acute Respiratory Infection Cases in Beijing, 2014 to 2015. Medicine (Baltimore). 2015;94(52):e2399.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. Jama. 2004;292(11):1333-40.
4. Jennings L, Huang QS, Barr I, Lee PI, Kim WJ, Buchy P, et al. Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. Influenza Other Respir Viruses. 2017.
5. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(3):e43-51.
6. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. Elife. 2015;4:e05055.
7. Franco LM, Bucasas KL, Wells JM, Nino D, Wang X, Zapata GE, et al. Integrative genomic analysis of the human immune response to influenza vaccination. Elife. 2013;2:e00299.
8. Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, et al. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics. 2017;7(4):826-45.
9. Harvala H, Smith D, Salvatierra K, Gunson R, von Wissmann B, Reynolds A, et al. Burden of influenza B virus infections in Scotland in 2012/13 and epidemiological investigations between 2000 and 2012. Euro Surveill. 2014;19(37).
10. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519-24.
11. Su S, Chaves SS, Perez A, D'Mello T, Kirley PD, Yousey-Hindes K, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis. 2014;59(2):252-5.
12. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013;21(7):350-8.
13. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61(2):263-83.
14. Stiver G. The treatment of influenza with antiviral drugs. Cmaj. 2003;168(1):49-56.
15. Kawai N, Ikematsu H, Iwaki N, Kawashima T, Maeda T, Mitsuoka S, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect. 2007;55(3):267-72.
16. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44(2):197-202.
17. Xu L, He D, Li Z, Zheng J, Yang L, Yu M, et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4(5):498-513.
18. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337(6100):1343-8.
19. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, et al. Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog. 2013;9(2):e1003150.
20. Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017;8:14234.
21. Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med. 2017;9(412).
22. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999;286(5447):2156-9.
23. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2(1):52-62.
24. MacLennan IC, Gulbranson-Judge A, Toellner KM, Casamayor-Palleja M, Chan E, Sze DM, et al. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev. 1997;156:53-66.
25. Gui X, Ge P, Wang X, Yang K, Yu H, Zhao Q, et al. Identification of a highly conserved and surface exposed B-cell epitope on the nucleoprotein of influenza A virus. J Med Virol. 2014;86(6):995-1002.
26. Ditzel H, Rasmussen JW, Erb K, Borup-Christensen P, Titlestad I, Lassen E, et al. Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Res. 1993;53(24):5920-8.
27. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827-35.
28. Velkov T. The specificity of the influenza B virus hemagglutinin receptor binding pocket: what does it bind to? J Mol Recognit. 2013;26(10):439-49.
29. Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat Microbiol. 2017;2(10):1415-24.
30. Vigil A, Estelles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M. Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses. Antimicrob Agents Chemother. 2018;62(5).
31. Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, et al. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem Biophys Res Commun. 2013;441(1):226-9.
32. Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, et al. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 2015;100(3):377-84.
33. Gautam S, Loh KC. Immunoglobulin-M purification--challenges and perspectives. Biotechnol Adv. 2011;29(6):840-9.
34. Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother. 2004;53(2):110-7.
35. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C. Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother Emphasis Tumor Immunol. 1995;17(3):151-60.
36. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109(6):2657-62.
37. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002(1):Cd001090.
38. Tchoudakova A, Hensel F, Murillo A, Eng B, Foley M, Smith L, et al. High level expression of functional human IgMs in human PER.C6 cells. MAbs. 2009;1(2):163-71.
39. Valasek C, Cole J, Hensel F, Ye P, Conner MA, Ultee ME. Production and purification of a PER. C6-expressed IgM antibody therapeutic. BioProcess Int. 2011;9(11):28-37.
40. Rasche L, Duell J, Morgner C, Chatterjee M, Hensel F, Rosenwald A, et al. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. PLoS One. 2013;8(5):e63414.
41. Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, Rheaume C, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One. 2012;7(6):e38929.
42. Maroof A, Yorgensen YM, Li Y, Evans JT. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014;10(1):e1003875.
43. Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines. 2012;11(5):595-607.
44. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010;6(2):e1000796.
45. Lin Q, Li T, Chen Y, Lau SY, Wei M, Zhang Y, et al. Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus. Journal of virology. 2018;92(17).
46. Muramatsu M, Yoshida R, Miyamoto H, Tomabechi D, Kajihara M, Maruyama J, et al. Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice. PLoS One. 2013;8(8):e71534.
47. Tewawong N, Suwannakarn K, Prachayangprecha S, Korkong S, Vichiwattana P, Vongpunsawad S, et al. Molecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014. PLoS One. 2015;10(1):e0116302.
48. Zhang TY, Yuan Q, Zhao JH, Zhang YL, Yuan LZ, Lan Y, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016;65(4):658-71.
49. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372-84.
50. Wang D, Fan F, Li Z, Liu X, Song S, Wei S, et al. Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli. Protein Expr Purif. 2017;133:110-20.
51. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012;109(23):9047-52.
52. O E, Lee YT, Ko EJ, Kim KH, Lee YN, Song JM, et al. Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination. J Virol. 2014;88(14):7764-75.
53. Yang D, Singh A, Wu H, Kroe-Barrett R. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. Anal Biochem. 2016;508:78-96.
54. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015;7(316):316ra192.
55. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-12.
56. Chen R, Weng Z. A novel shape complementarity scoring function for protein-protein docking. Proteins. 2003;51(3):397-408.
57. Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins. 2003;53(3):693-707.